Zie ook in gerelateerde artikelen

4 november 2019: . 2016; 5(1): 1885. Published online 2016 Oct 27

Wanneer patienten met neustumoren naast chemo en bestraling ook injecties krijgen als immuuntherapie met gendicine, een adenovirus-P53 gericht op mutaties in het P-53 genen gebied dan verbetert de ziektevrije tijd en overall overleving statistisch significant. 

The results indicated the complete remission (CR) and overall response (OR) in the combination therapy group were significantly improved compared with the CRT/RT group (CR:RR = 2.03, 95% CI 1.66–2.48, p < 0.00001; 

Dit blijkt uit een meta-analyse van 12 gerandomiseerde studies.

Our search strategy identified 115 potentially relevant studies, and a total of twelve literatures were adopted in the end. The characteristics of the twelve studies (Zhang et al. ; Pan et al. ; Lan et al. ; Qin et al. ; Wang et al. ; Li ; Si et al. ; Chen et al. ) were summarized in Table 1. A total of 566 patients were included in the meta-analysis, of whom 298 received CRT/RT combined with rAd-p53 and 268 were treated with CRT/RT alone.

As shown in Figs. 1,2,2, the analysis results indicated that the CR and OR in the combination therapy group were significantly improved compared with the CRT/RT group (CR:RR = 2.03, 95% CI 1.66–2.48, p < 0.00001; OR:RR = 1.23, 95% CI 1.13–1.33, p < 0.00001).

An external file that holds a picture, illustration, etc.
Object name is 40064_2016_3574_Fig1_HTML.jpg

Forest plot for the meta-analysis of complete remission (CR) rate of primary tumor

Het volledige studierapport: Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis is gratis in te zien.

Hier het abstract van deze reviewstudie met referentielijst:

. 2016; 5(1): 1885.
Published online 2016 Oct 27. doi: 10.1186/s40064-016-3574-6
PMCID: PMC5083707
PMID: 27843742

Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis

Abstract

To compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC). We searched all the eligible studies from the Pubmed, Cochran Library, Embase, Web of science, Wanfang database and Chinese National Knowledge Infrastructure (CNKI). A total of twelve studies including 566 participants met the criteria to perform a meta-analysis. The results indicated the complete remission (CR) and overall response (OR) in the combination therapy group were significantly improved compared with the CRT/RT group (CR:RR = 2.03, 95% CI 1.66–2.48, p < 0.00001; OR:RR = 1.23, 95% CI 1.13–1.33, p < 0.00001), and patients who received the combination therapy showed significantly prolonged 1- and 2-year overall survival (OS), 2 year disease-free survival (DFS) rate and 2 year recurrence-free survival (RFS) rate (1 year OS:RR = 1.08, 95% CI 1.00–1.17, p = 0.04; 2 year OS:RR = 1.12, 95% CI 1.00–1.26, p = 0.04; 2 year DFS:RR = 1.41, 95% CI 1.09–1.83, p = 0.008; 2 year RFS:RR = 1.16, 95% CI 1.03–1.31, p = 0.02), but there was no significance in 3 year OS rate and 2 year distant metastases-free survival (DMFS) rate (3 year OS:RR = 1.28, 95% CI 1.00–1.62, p = 0.05; 2 year DMFS:RR = 1.05, 95% CI 0.89–1.24, p = 0.55). Furthermore, CRT/RT combined with rAd-p53 could not aggravate the myelosuppression versus CRT/RT alone (RR = 0.79, 95% CI 0.51–1.23, p = 0.30). The results demonstrated CRT/RT combined with rAd-p53 can result in enhanced survival and better clinical responses of patients with NPC. Therefore, rAd-p53 has great potential as an effective therapy for NPC.

References

  • Chen CB, Pan JJ, Xu LY. Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trial. Zhonghua Yi Xue Za Zhi. 2003;83:2033–2035. [PubMed[]
  • Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet (London, England) 2015;387:1012–1024. doi: 10.1016/S0140-6736(15)00055-0. [PubMed] [CrossRef[]
  • Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev. 2004;23:237–257. doi: 10.1023/B:CANC.0000031764.81141.e4. [PubMed] [CrossRef[]
  • Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009;125:1735–1738. doi: 10.1002/ijc.24486. [PMC free article] [PubMed] [CrossRef[]
  • Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–129. doi: 10.1038/nrc992. [PubMed] [CrossRef[]
  • Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (New York, NY) 2000;287:1824–1827. doi: 10.1126/science.287.5459.1824. [PubMed] [CrossRef[]
  • Hughes J, Alusi G, Wang Y. Gene therapy and nasopharyngeal carcinoma. Rhinology. 2012;50:115–121. [PubMed[]
  • Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [PubMed] [CrossRef[]
  • Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg. 2002;235:493–498. doi: 10.1097/00000658-200204000-00006. [PMC free article] [PubMed] [CrossRef[]
  • Lan G, Su J, Si Y, He C, Huang B, Zhang Z. Clinical effect of rAd-p53 combined with radiotherapy and chemotherapy on treatment of advanced nasopharyngeal carcinoma. J Pract Med. 2011;27:2341–2344. []
  • Lan G, Si Y, Qin Y, Deng Z, He C, Huang B. Recombinant adenoviral human p53 gene combined with radio- and chemotherapy in treatment of advanced nasopharyngeal carcinoma: a randomized clinical study. J Clin Oncol. 2012;30(15 suppl 1):5558. []
  • Li HT. Effect of recombinant human P53 adenovirus injection combined with radiotherapy and chemotherapy in treatment of advanced nasopharyngeal carcinoma. J Med Theor Prac. 2012;25:1083–1084. []
  • Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5:423–428. doi: 10.1016/S1535-6108(04)00119-9. [PubMed] [CrossRef[]
  • Ma JT, Han CB, Zhao JZ, Jing W, Zhou Y, Huang LT, Zou HW. Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells. Oncol Lett. 2012;4:529–533. [PMC free article] [PubMed[]
  • Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV’s anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010;10:319–340. doi: 10.2174/156652310793180706. [PMC free article] [PubMed] [CrossRef[]
  • Nicolson SC, Samulski RJ. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol. 2014;88:4132–4144. doi: 10.1128/JVI.02660-13. [PMC free article] [PubMed] [CrossRef[]
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–614. doi: 10.1002/humu.10081. [PubMed] [CrossRef[]
  • Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B, Lu YY. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:799–804. doi: 10.1200/JCO.2008.18.9670. [PubMed] [CrossRef[]
  • Qin Y, Weng J, Lan G, Wei H, Huang B, Sun J, Si Y. Effect of p53 gene therapy on the local immunity and the efficacy of patients with nasopharyngeal carcinoma. J Chin Otorhinolaryngol Head Neck Surg (China) 2012;26:980–983. [PubMed[]
  • Shiomitsu K, Sajo E, Xia X, Hunley DW, Mauldin GE, Li S, Mauldin GN. Radiosensitivity of canine osteosarcoma cells transfected with wild-type p53 in vitro. Vet Comp Oncol. 2008;6:193–200. doi: 10.1111/j.1476-5829.2008.00160.x. [PubMed] [CrossRef[]
  • Si YF, He CC, Lan GP, Huang B, Zhang Z, Lu JL, Zhou RJ, Jiang H. Recombinant adenovirus p53 agent injection combined with radiotherapy and chemotherapy for intermediate and advanced stage nasopharyngeal carcinoma. Chin J Clin Oncol. 2009;36:1031–1039. []
  • Sun GG, Zhang J, Ma XB, Wang YD, Cheng YJ, Hu WN. Overexpression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with nasopharyngeal carcinoma. Pathol Oncol Res. 2015;21:283–291. doi: 10.1007/s12253-014-9819-1. [PubMed] [CrossRef[]
  • Wang JC, Wang F, Kong LL, Wu NM, Zhang KL, Zhang L. Recombinant adenovirus p53 combince with radiotherapy in treat ment of nasopharyngeal carcinoma. Acta Universitatis Medicinalis Anhui. 2010;45:235–237. []
  • Wang XH, Wang JG, Zhang J, Hu WN, Zhang RJ. Clinical observations of recombinant adenovirus-p53 combined with radiotherapy on nasopharyngeal squamous carcinoma. Mod J Int Tradit Chin West Med. 2012;21:924–925, 934. []
  • Zhang S, Xiao S, Sun Y, Liu C, Su X, Li D, Xu G, Zhu G, Xu B (2006). Clinical trial of recombinant adenovirus-p53 (Gendicine) combined with radiotherapy in nasopharyngeal carcinoma patients. Mol Therapy 13: 280
  • Zhang SW, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B. Long-Term outcomes of combination of recombinant adenovirus-p53 (Gendicine) with radiotherapy in nasopharyngeal carcinoma. Hum Gene Ther. 2007;18:955–993. doi: 10.1089/hum.2007.1028. [CrossRef[]
  • Zhang LZ, Zu MZ, Tang TT, Wang JW, Xin YX, Liu GL, Zheng JZ. A phase II study of recombinant adeno-viral human p53 gene combined with radiotherapy and radio- and chemo-therapy in treatment of patients with advanced nasopharyngeal carcinoma. Hum Gene Ther. 2011;22:A125. doi: 10.1089/hum.2011.003. [CrossRef[]

Articles from SpringerPlus are provided here courtesy of Springer-Verlag

Plaats een reactie ...

Reageer op "Immuuntherapie met Gendicine , een adenovirus P-53 naast chemotherapie geeft uitstekende resultaten bij patienten met neustumoren"


Gerelateerde artikelen
 

Gerelateerde artikelen

Immuuntherapie met Gendicine >> Gentherapie met p53 virus >> Gentherapie met p53 virus >>